Status and phase
Conditions
Treatments
About
This is a phase II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy in patients with NSCLC.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
296 participants in 7 patient groups
Loading...
Central trial contact
Weifeng Song, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal